Beijing Ice-Biosicience Co.,Ltd

In 2020, ICH E14/S7B cardiac safety regulations was updated: The role of in vitro assays was  expanded and the “Double-Negative” scenario was suggested. Therefore, we develop a systematic strategy to assess preclinical cardiac safety: CardiacOne^TM   

Our CardiacOne^TM will assess cardiotoxicity in three aspects: electrophysiological abnormalities, contractile dysfunction, and structural toxicity

Cardiac pharmacological study platform

 Multiple cardiac ion channel patch clamp or automated patch clamp (Beyond CiPA related channels)

 Cardiac pharmacological study using acutely isolated cardiomyocytes (from human, monkey, canine, rabbit, Guinea pig, rats or mice) or iPSCs-derived cardiomyocytes

 Langendorff perfusion of isolated heart and in vivo ECG recording

 Cardiac action potential assays of Purkinje fibers and papillary muscle